• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Byvalson (nebivolol and valsartan)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Byvalson (nebivolol and valsartan)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Byvalson (nebivolol and valsartan 5 mg/ 80 mg tablet) is a fixed-dose combination of nebivolol - a beta-adrenergic receptor blocking agent that is preferentially beta-1 selective, and valsartan - an angiotensin II receptor blocker.

    Byvalson is specifically indicated for the treatment of hypertension, to lower blood pressure.

    Byvalson is supplied as a tablet for oral administration. The recommended dose is as follows: as initial therapy and in patients not adequately controlled on valsartan 80 mg or nebivolol up to and including 10 mg, the recommended dose is 5 mg/ 80 mg taken orally once daily. Maximum antihypertensive effects are attained within 2 to 4 weeks. Byvalson may be substituted for its components in patients already receiving 5 mg nebivolol and 80 mg valsartan.

    Clinical Results

    FDA Approval

    The FDA approval of Byvalson was based on a Phase III, double-blind, placebo-controlled, dose-escalating, 8-week efficacy and safety study, which randomized approximately 4,100 patients with Stage 1 or 2 hypertension. Treatment with Byvalson 5 mg/ 80 mg for 4 weeks resulted in placebo-adjusted reductions from baseline in systolic (SBP) and diastolic (DBP) blood pressure of -8.3 and -7.2 mmHg, respectively. Treatment with Byvalson 5 mg/ 80 mg resulted in greater reductions in SBP and DBP than did treatment with nebivolol 5 mg alone (p<0.0001 for both SBP and DBP) or valsartan 80 mg, alone (p=0.0007 for SBP and p<0.0001 for DBP). The overall rate of adverse events was similar across treatment groups and placebo during this 4 week period.

    Side Effects

    Adverse effects associated with the use of Byvalson may include, but are not limited to, the following:

    • skull hypoplasia
    • anuria
    • hypotension
    • renal failure
    • death

    Byvalson comes with a Black Box warning of fetal toxicity. When pregnancy is detected, discontinue Byvalson as soon as possible. Drugs, including Byvalson, that act directly on the reninangiotensin system can cause injury and death to the developing fetus. 

    Mechanism of Action

    Byvalson (nebivolol and valsartan 5 mg/ 80 mg tablet) is a fixed-dose combination that combines two FDA approved, once daily, blood pressure lowering agents with different mechanisms of action. Nebivolol is a beta-adrenergic receptor blocking agent that is preferentially beta-1 selective. Valsartan is an angiotensin II receptor blocker (ARB) that blocks the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland, thereby blocking its vasoconstrictor and aldosterone-secreting effects.

    Additional Information

    For additional information regarding Byvalson or hypertension, please visit http://www.byvalson.com/

    Approval Date: 2016-06-01
    Company Name: Allergan
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing